EUVIMEDEUVIMED entdecken
Leitlinie

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026

William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Greg Bociek, Daniel Boyer, Matthew Cortese, Larry Cripe, Christopher D'Angelo, Elijah Darnell, Randall S Davis, Herbert Eradat und 25 weitere

Journal of the National Comprehensive Cancer Network · 2026-03 · 24 (3) · 68-80

DOI: 10.6004/jnccn.2026.0012 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-03. Verfasst von William G Wierda und 36 weiteren Autor:innen. Beteiligte Einrichtung: 1The University of Texas MD Anderson Cancer Center. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 156 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Lymphocytic, Chronic, B-CellHumansProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Practice Guidelines as Topic

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • 1The University of Texas MD Anderson Cancer Center.
  • 2Dana-Farber/Brigham and Women's Cancer Center.
  • 3Mass General Cancer Center.
  • 4UT Southwestern Simmons Comprehensive Cancer Center.
  • 5Fred & Pamela Buffett Cancer Center.
  • 6University of Michigan Rogel Cancer Center.

Zitieren

APA

Wierda, W. G., Brown, J., Abramson, J. S., Awan, F., Bociek, G., Boyer, D., Cortese, M., Cripe, L., D'Angelo, C., Darnell, E., Davis, R. S., Eradat, H., Esteghamat, N., Fitzgerald, L., Fletcher, C. D., Gaballa, S., Huntington, S., Kahl, B., Kamdar, M., …, & Sundar, H. (2026). NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. Journal of the National Comprehensive Cancer Network, 24(3), 68-80. https://doi.org/10.6004/jnccn.2026.0012

Vancouver

Wierda WG, Brown J, Abramson JS, Awan F, Bociek G, Boyer D, et al. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. Journal of the National Comprehensive Cancer Network. 2026;24(3):68-80. doi:10.6004/jnccn.2026.0012

BibTeX
@article{Wierda2026,
  author = {Wierda, William G and Brown, Jennifer and Abramson, Jeremy S and Awan, Farrukh and Bociek, Greg and Boyer, Daniel and Cortese, Matthew and Cripe, Larry and D'Angelo, Christopher and Darnell, Elijah and Davis, Randall S and Eradat, Herbert and Esteghamat, Naseem and Fitzgerald, Lindsey and Fletcher, Christopher D and Gaballa, Sameh and Huntington, Scott and Kahl, Brad and Kamdar, Manali and Kipps, Thomas J and Ma, Shuo and Mosse, Claudio A and Nakhoda, Shazia and Parikh, Sameer A and Riedell, Peter and Schorr, Andrew and Schuster, Stephen and Seshadri, Madhav and Shanafelt, Tait and Siddiqi, Tanya and Sitlinger, Andrea and Thompson, Meghan and Ujjani, Chaitra and Wagner-Johnston, Nina and Woyach, Jennifer A and Dwyer, Mary and Sundar, Hema},
  title = {NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {3},
  pages = {68--80},
  doi = {10.6004/jnccn.2026.0012}
}
Kostenlos starten →